246 related articles for article (PubMed ID: 16214189)
1. Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility.
Wood E; Kerr T; Stoltz J; Qui Z; Zhang R; Montaner JS; Tyndall MW
Public Health; 2005 Dec; 119(12):1111-5. PubMed ID: 16214189
[TBL] [Abstract][Full Text] [Related]
2. Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility.
Milloy MJ; Kerr T; Mathias R; Zhang R; Montaner JS; Tyndall M; Wood E
Am J Drug Alcohol Abuse; 2008; 34(4):499-509. PubMed ID: 18584579
[TBL] [Abstract][Full Text] [Related]
3. Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility.
Wood RA; Wood E; Lai C; Tyndall MW; Montaner JS; Kerr T
Int J Drug Policy; 2008 Jun; 19(3):183-8. PubMed ID: 18367389
[TBL] [Abstract][Full Text] [Related]
4. Do supervised injecting facilities attract higher-risk injection drug users?
Wood E; Tyndall MW; Li K; Lloyd-Smith E; Small W; Montaner JS; Kerr T
Am J Prev Med; 2005 Aug; 29(2):126-30. PubMed ID: 16005809
[TBL] [Abstract][Full Text] [Related]
5. Use of supervised injection facilities and injection risk behaviours among young drug injectors.
Bravo MJ; Royuela L; De la Fuente L; Brugal MT; Barrio G; Domingo-Salvany A;
Addiction; 2009 Apr; 104(4):614-9. PubMed ID: 19215603
[TBL] [Abstract][Full Text] [Related]
6. Condom use among injection drug users accessing a supervised injecting facility.
Marshall BD; Wood E; Zhang R; Tyndall MW; Montaner JS; Kerr T
Sex Transm Infect; 2009 Apr; 85(2):121-6. PubMed ID: 18812391
[TBL] [Abstract][Full Text] [Related]
7. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT
Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668
[TBL] [Abstract][Full Text] [Related]
8. Injection drug users' perceptions regarding use of a medically supervised safer injecting facility.
Petrar S; Kerr T; Tyndall MW; Zhang R; Montaner JS; Wood E
Addict Behav; 2007 May; 32(5):1088-93. PubMed ID: 16930849
[TBL] [Abstract][Full Text] [Related]
9. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users.
Wood E; Kerr T; Small W; Li K; Marsh DC; Montaner JS; Tyndall MW
CMAJ; 2004 Sep; 171(7):731-4. PubMed ID: 15451834
[TBL] [Abstract][Full Text] [Related]
10. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
12. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004.
Holtzman D; Barry V; Ouellet LJ; Des Jarlais DC; Vlahov D; Golub ET; Hudson SM; Garfein RS
Prev Med; 2009 Aug; 49(1):68-73. PubMed ID: 19410600
[TBL] [Abstract][Full Text] [Related]
13. [Risk factors for hepatitis C among injecting drug users in Oslo].
Dalgard O; Egeland A; Ervik R; Vilimas K; Skaug K; Steen TW
Tidsskr Nor Laegeforen; 2009 Jan; 129(2):101-4. PubMed ID: 19151801
[TBL] [Abstract][Full Text] [Related]
14. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
[TBL] [Abstract][Full Text] [Related]
15. HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates.
de la Fuente L; Toro C; Soriano V; Brugal MT; Vallejo F; Barrio G; Jiménez V; Silva T;
J Clin Virol; 2006 Mar; 35(3):244-9. PubMed ID: 16143565
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran.
Zamani S; Ichikawa S; Nassirimanesh B; Vazirian M; Ichikawa K; Gouya MM; Afshar P; Ono-Kihara M; Ravari SM; Kihara M
Int J Drug Policy; 2007 Oct; 18(5):359-63. PubMed ID: 17854723
[TBL] [Abstract][Full Text] [Related]
17. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
Braitstein P; Li K; Kerr T; Montaner JS; Hogg RS; Wood E
AIDS Care; 2006 Oct; 18(7):690-3. PubMed ID: 16971276
[TBL] [Abstract][Full Text] [Related]
18. HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment.
Tyndall MW; Wood E; Zhang R; Lai C; Montaner JS; Kerr T
Harm Reduct J; 2006 Dec; 3():36. PubMed ID: 17176481
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack.
Macías J; Palacios RB; Claro E; Vargas J; Vergara S; Mira JA; Merchante N; Corzo JE; Pineda JA
Liver Int; 2008 Jul; 28(6):781-6. PubMed ID: 18312289
[TBL] [Abstract][Full Text] [Related]
20. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
